Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

Detalles Bibliográficos
Autores principales: Ravandi, F, Pigneux, A, DeAngelo, D J, Raffoux, E, Delaunay, J, Thomas, X, Kadia, T, Kantarjian, H, Scheuenpflug, J, Zhao, C, Guo, W, Smith, B D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735070/
https://www.ncbi.nlm.nih.gov/pubmed/26657199
http://dx.doi.org/10.1038/bcj.2015.103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735070/
https://www.ncbi.nlm.nih.gov/pubmed/26657199
http://dx.doi.org/10.1038/bcj.2015.103

Ejemplares similares